<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02929030</url>
  </required_header>
  <id_info>
    <org_study_id>NANOxijing001</org_study_id>
    <nct_id>NCT02929030</nct_id>
  </id_info>
  <brief_title>Clinical Performance of Nano Plus Sirolimus-Eluting Stents in Patients With Coronary Artery Disease</brief_title>
  <official_title>Safety and Efficacy of Polymer-free Sirolimus-eluting Coronary Stents in Patients With Coronary Artery Disease.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Xijing Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Nanjing First Hospital, Nanjing Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Xijing Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study aims to evaluate the safety and efficacy of polymer-free sirolimus-eluting coronary
      stent system (NANO plus) in patients with coronary artery disease . The primary endpoint is
      target lesion failure, a composite endpoint of cardiac death, target vessel related
      myocardial infarction and clinically-driven target lesion revascularization at 1 year
      follow-up.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective, multicenter, single arm clinical registry investigating the safety and
      efficacy of polymer-free sirolimus-eluting coronary stent system (NANO plus) in patients with
      coronary artery disease . In total, we plan to recruit 2500 patients in real world setting.
      The patients will be followed clinically at 1-, 6- month and 1-, 2-, 3-, 4-, 5-year. All
      clinical data will be collected and managed by statistical center, clinical endpoint
      adjudication committee.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2016</start_date>
  <completion_date type="Anticipated">January 2022</completion_date>
  <primary_completion_date type="Anticipated">January 2018</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>5 Years</target_duration>
  <primary_outcome>
    <measure>target lesion failure (TLF)</measure>
    <time_frame>12 months</time_frame>
    <description>cardiac death, target vessel related myocardial infarction and/or clinically driven target lesion revascularization</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Target lesion failure</measure>
    <time_frame>1、6、12、24、36、48、60 months</time_frame>
    <description>a composite endpoint of cardiac death, target lesion related myocardial infarction, and/or target lesion revascularization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient oriented composite endpoint</measure>
    <time_frame>1、6、12、24、36、48、60 months</time_frame>
    <description>a composite endpoint of all cause death, all myocardial infarction and all revascularization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>all cause death</measure>
    <time_frame>1、6、12、24、36、48、60 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>cardiac death</measure>
    <time_frame>1、6、12、24、36、48、60 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Myocardial infarction</measure>
    <time_frame>1、6、12、24、36、48、60 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stent thrombosis</measure>
    <time_frame>1、6、12、24、36、48、60 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target lesion revascularization</measure>
    <time_frame>1、6、12、24、36、48、60 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target vessel revascularization</measure>
    <time_frame>1、6、12、24、36、48、60 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>target lesion failure</measure>
    <time_frame>1、6、24、36、48、60 months</time_frame>
    <description>cardiac death, target vessel related myocardial infarction and/or clinically driven target lesion revascularization</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">2500</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>NANO Plus SES</arm_group_label>
    <description>All patients will be treated with NANO plus sirolimus-eluting stent. Patients will be prescribed with clopidogrel and aspirin before the index procedure. The lesions will be predilted if necessary before stent implantation. There are no specific limitations on coronary lesions according the study criteria.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Nano</intervention_name>
    <description>The stent system comprises of 2 components: stent steel platform, antiproliferative drug sirolimus, and stent balloon</description>
    <arm_group_label>NANO Plus SES</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with coronary artery disease
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18-85 years old, male or non-pregnancy female;

          -  Patients with coronary artery disease who match the indication of stent implantation;

          -  Patients who can understand the nature of the study, agree to participate and accept
             clinical follow-up;

        Exclusion Criteria:

          -  Patients who can not tolerate the material or medication in this study;

          -  Pregnancy or lactation women

          -  Patients who had participated in another investigational drug or device trial that has
             not completed the primary endpoint;

          -  Patients are, in the opinion of the investigator, unable to comply with the
             requirements of the study protocol
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lin Tao, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Xijing Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Yao-Jun Zhang, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Nanjing First Hospital, Nanjing Medical University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Yue Li, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The First Clinical Hospital affiliated to Harbin Medical University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Zhiqi Sun, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Daqing oilfield central hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Chen Wang, PhD</last_name>
    <phone>15802929290</phone>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jin-Zan Cai, MSc</last_name>
    <phone>15720800327</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Xijing Hospital</name>
      <address>
        <city>Xi'an</city>
        <state>Shanxi</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chen Wang</last_name>
      <phone>15802929290</phone>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Suwannasom P, Onuma Y, Benit E, Gach O, von Birgelen C, Hofma SH, Sotomi Y, Bo X, Zhang YJ, Gao R, García-García HM, Wykrzykowska JJ, de Winter RJ, Serruys PW. Evaluation of vascular healing of polymer-free sirolimus-eluting stents in native coronary artery stenosis: a serial follow-up at three and six months with optical coherence tomography imaging. EuroIntervention. 2016 Aug 5;12(5):e574-83. doi: 10.4244/EIJV12I5A97.</citation>
    <PMID>27497357</PMID>
  </reference>
  <reference>
    <citation>Zhang Y, Chen F, Muramatsu T, Xu B, Li Z, Ge J, He Q, Yang Z, Li S, Wang L, Wang H, He B, Li K, Qi G, Li T, Zeng H, Peng J, Jiang T, Zeng Q, Zhu J, Fu G, Bourantas CV, Serruys PW, Huo Y. Nine-month angiographic and two-year clinical follow-up of polymer-free sirolimus-eluting stent versus durable-polymer sirolimus-eluting stent for coronary artery disease: the Nano randomized trial. Chin Med J (Engl). 2014;127(11):2153-8.</citation>
    <PMID>24890170</PMID>
  </reference>
  <verification_date>December 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 6, 2016</study_first_submitted>
  <study_first_submitted_qc>October 6, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 10, 2016</study_first_posted>
  <last_update_submitted>December 29, 2016</last_update_submitted>
  <last_update_submitted_qc>December 29, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 30, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Xijing Hospital</investigator_affiliation>
    <investigator_full_name>Tao Ling</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sirolimus</mesh_term>
    <mesh_term>Everolimus</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

